Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Trial to Evaluate the Safety and Efficacy of iPSC-Derived Dopaminergic Progenitors in the Treatment of Parkinson's Disease

Trial Profile

A Phase I/II Trial to Evaluate the Safety and Efficacy of iPSC-Derived Dopaminergic Progenitors in the Treatment of Parkinson's Disease

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2018

At a glance

  • Drugs Dopaminergic neural progenitor cell therapy Sumitomo Dainippon Pharma (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Aug 2018 New trial record
    • 30 Jul 2018 According to a Kyoto University media release and announcement posted on CiRAs website, Kyoto University Hospital, in partnership with the Center for iPS Cell Research and Application (CiRA), Kyoto University, has planned physician-initiated clinical trials (this and phase III trial) for Parkinson's disease that transplants dopaminergic progenitors generated from induced pluripotent stem (iPS) cells.
    • 30 Jul 2018 According to a Kyoto University media release and announcement posted on CiRAs website, the clinical trial notification was submitted to the Pharmaceutical and Medical Devices Agency on 4 Jun 2018 and the clinical trials (this and phase III trial) are scheduled to begin on 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top